The use of the tyrosine kinase inhibitors (TKIs) imatinib, dasatinib, and nilotinib has revolutionised the care of patients with chronic myeloid leukemia (CML) [1-3]. We now have more than 6 years ...
No takes yet. Share an insight, caveat, or question.
Mattison et al. (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: